Effectiveness of topical Nano-minoxidil and minoxidil on treatment of patients with androgenetic alopecia

Determining and comparing the effectiveness of topical Nano-minoxidil and minoxidil on treatment of patients with androgenetic alopecia aged between 18-50 years

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101130005280N62

Enrollment

Registered

2023-06-13

Start date

2023-06-15

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia. Androgenic alopecia

Interventions

Intervention 1: Intervention group: In this group, patients are treated with 1 cc of 0.5% Nano-minoxidil (produced by Dr. Ali Moradi and Dr. Majid Daroudi in the nanobiotechnology department of the me

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients are between 18 and 50 years of age Patients with androgenetic alopecia (Sinclair stage 2-5)

Exclusion criteria

Exclusion criteria: Hypertension Skin lesions such as psoriasis or blister on the scalp Severe Seborrhoeic dermatitis History of allergic reaction to minoxidil

Design outcomes

Primary

Measure	Time frame
Hair density. Timepoint: Every 2 months for 6 months. Method of measurement: Trichoscopy.;Hair diameter. Timepoint: Every 2 months for 6 months. Method of measurement: Trichoscopy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShatila Torabi

Mashhad University of Medical Sciences

TorabiSh@mums.ac.ir+98 51 3802 2406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026